Skip to content

Penehyclidine for prevention of postoperative nausea and vomiting following temporomandibular joint surgery

Penehyclidine for prevention of postoperative nausea and vomiting following temporomandibular joint surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089370
Enrollment
Unknown
Registered
2024-09-06
Start date
2024-09-06
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

temporomandibular joint anterior disc displacement without reduction

Interventions

Pneheydidine hydrochloride group:Penehyclidine hydrochloride was given 0.5 mg intravenously during anesthesia induction.
saline group:Saline was given 5 ml intravenously during anesthesia induction.

Sponsors

The Afliated Stomatological Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with irretrievable anterior disk displacement of temporomandibular joint and proposed to undergo surgery; 2. Aged between 12 and 50 years old, ASA I to II level.

Exclusion criteria

Exclusion criteria: 1. Known allergies to the drugs used in this study, including penehyclidine hydrochloride; 2. Mental retardation, mental or neurological disorders; 3. Use antiemetics, emetics, opioids or glucocorticoids within 3 days before surgery; 4. Complicated with severe respiratory, circulatory, hepatic and renal insufficiency and central system diseases.

Design outcomes

Primary

MeasureTime frame
The incidence of PONV;

Secondary

MeasureTime frame
Severity of postoperative nausea;

Countries

China

Contacts

Public ContactLiu Li

The Afliated Stomatological Hospital of Nanjing Medical University

2024760268@qq.com+86 138 5152 8473

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026